MORRIS LASTER, MD - Kenes

MORRIS LASTER, MD
May, 2007
Home: 11 Reuven Shari
PERSONAL
Jerusalem, Israel 97246
Tel: +972-2-586-6740
Fax: +972-2-587-9529
Email: morris@biolinerx.com
Age: 43
Status: Married to Gail (nee Polin)
Gabriella 17, Sarit 14, and Chen 10
Citizenship: US and Israeli
EMPLOYMENT
2003- BioLineRx Ltd. (TASE: BLRX); Jerusalem, Israel
CEO & Director
A drug development pipeline company founded by Teva, Giza, Pitango,
Hadasit, and the Jerusalem Development Authority.
BioLineRx a clinical stage publicliy traded drug development company
designated as Israel’s National Biotechnology Accelerator has raised over $100
million in financing from TASE, private investors and the Israeli government.
(www.biolinerx.com)
1997-2002 Keryx Biopharmaceuticals Inc.; Boston, USA and Jerusalem, Israel
Chairman & CEO
1990-1996 Paramount Capital Investments LLC; New York, NY
Vice President, Medical Venture Capital
COMPANIES FOUNDED
1997 Keryx Biopharmaceuticals (Nasdaq: KERX; AIM:KRX)
Boston, USA and Jerusalem, Israel
Founder and Chairman since inception. IPO in July 2000. Keryx developed
Phase III compound to treat diabetic nephropathy and successfully negotiated
Subpart H accelerated approval strategy with US FDA. First company to
simultaneously list on London AIM and NASDAQ exchanges. Raised over $60
million in public and private financings.
1992 XTL Biopharmaceuticals; (NASDAQ: XTLB; LSE: XTL; TASE: XTL),
Founder, initial interim CEO and member of initial Scientific Advisory Board.
Currently developing human monoclonal antibodies to treat Hepatits B and C
infections. Both compounds in Phase 2 clinical development.
1991 Progenitor Inc; Menlo Park, CA
Founder, interim CEO, former member of Board of Directors and Scientific
Advisory Board. Public NASDAQ offering managed by Lehman Brothers and
Genesis Merchant Bank in 1997.

MORRIS LASTER, MD
Page 2
COMPANIES FOUNDED continued
1990 Neose Technologies (Nasdaq: NTEC); Horsham, PA
Identified technology, performed due diligence, negotiated license agreement
with University of Pennsylvania, wrote initial business plan and recruited
management. NASDAQ offering managed by Smith Barney and Vector
Securities in 1996.
BOARD MEMBERSHIPS
Current -BioLineRx
-Start-Up Jerusalem- Public Service organization dedicated to promoting
economic development of Jerusalem
-Course in Pharmaceutical Medicine Tel Aviv University Medical School
CLINICAL EXPERIENCE
1993, 1995-1996 Hadassah University Hospital, Jerusalem, Israel
Resident, Orthopedic Surgery
1990-1991 Case Western Reserve University Hospital, Cleveland, Ohio
Resident, General Surgery
MILITARY
1995-Present Israel Defense Forces- Reserve Duty
Captain (Res.), Medical Corps
1993-1995 Israel Defense Forces- Active Duty
Lieutenant, Physician, Paratrooper Corps
EDUCATION
1986-1990 SUNY Health Science Center At Brooklyn (SUNY HSCB); Brooklyn, NY
MD; May 15, 1990
Awards
University of Texas Medical Branch Surgery Award (1988)
Roche Laboratories Award for Excellence in Basic Science Research;
First Place - National Student Research Forum (1988)
National Institutes of Health Summer Research Fellow (1987)
SUNY HSCB Alumni Association Summer Research Award (1987)
Engles Scholarship (1987-1990)
1982-1985 State University of New York at Albany; Albany, NY
B.S. in Biology; Magna Cum Laude, December 1985

MORRIS LASTER, MD
Page 3
BOARD CERTIFICATION
1991 Diplomate National Board of Medical Examiners (USA)
Certificate Number 387204
MEDICAL LICENSE
1993 Israeli Medical License Number 26753
1990 Ohio State Medical License Number 062626
PATENTS
-An Implantable Device for the Treatment of ESRD and Use Thereof (In submission)
-Conjugates Capable of Crossing the Blood-Brain Barrier (US Provisional No 60/674,302)
-Bone Marrow as a Site For Transplantation (Granted US 6,463,933, Australia)
-Compounds for the Modulation of Kinase Associated Signal Transduction (US Patent
Application Ser. No. 10/205302)
-Methods Using Glycosaminoglycans For The Treatment of Nephropathy (US Patent
Application Ser. No. 11/124,531)
-Use of Sulodexide for the Treatment of IBD (US Patent Application Ser. No.10/147681).
ASSOCIATIONS
BIO Biotechnology Organization
Israel Biotechnology Organization
American Medical Association
Israeli Medical Association
American Association for the Advancement of Science
American Society for Gene Therapy
PUBLICATIONS
1) Anis Y, Leshem O, Reuveni H, Wexler I, Ben Sasson R, Yahalom B, Laster
M, Raz I, Ben Sasson S, Shafrir E, Ziv E. Antidiabetic Effect of Novel
Modulating Peptides of G-Protein Coupled Kinase in Experimental Models
of Diabetes. Diabetologia. 47:1232-1244 (2004)
2) Niv M, Rubin H, Cohen J, Licht T, Peretzman-Shemer A, Cnaan E,
Tartakovski A, Stein I, Albeck S, Tsirulnikov L, Goldenberg-Furmanov M,
Weinstein I, Tobi D, Seger R, Laster M, Ben-Sasson SA, Reuveni H. A
Novel Technology for Sequence Based kinase inhibitors for therapeutic and
target identification applications. J Biol Chem. 279(2):1242-55 (2004)
3) Schachter PP, Ayesh S, Schneider T, Laster M, Czerniak A, Hochberg A.
Expression of kinase genes in primary hyperparathyroidism: Adenoma versus
hyperplastic parathyroid tissue. Surgery 132(6):1094-9 (2002)
4) Ayesh S, Matouk I, Schneider T, Ohana P, Laster M, Al-Sharef W, deGroot
N, Hochberg A. The Possible Physiological Role of H19 RNA. Molecular
Carcinogenesis 35(2):63-74 (2002)

MORRIS LASTER, MD
Page 4
5) Robenshtok E, Laster M, Katz L, Sagi R. Viral Hemorrhagic Fever As A
Biological Weapon. Harefuah 141:96-99(2002)
6) Ohana P, Bibi O, Matouk I, Levi C, Berman T, Ariel I, Ayesh S, Laster, M,
Giladi H, de Groot N, Hochberg A. The Use if H19 Regulatory Sequences for
Targeted Gene Therapy in Cancer. International Journal of Cancer. 98:645-
650(2002)
7) Honigman A, Zeira E, Ohana P, Abramovitz R, Tavor E, Bar I, Zilberman Y,
Rabinovsky R, Gazit D, Joseph A, Panet A, Shai E, Palmon A, Laster M,
Galun E. Imaging Transgene Expression in Live Animals. Molecular Therapy
4(3):239-249(2001)
8) Banet G, Bibi O, Matouk I, Ayesh S, Laster M, Molnar-Kimber K,
Tykocinski M, deGroot N, Hochberg A, Ohana P.. Chracterization of Human
and Mouse H19 Regulatory Sequences. Molecular Biology Reports.
27(3):157-65 (2000)
9) Abdul-Ghani R, Ohana P, Ayesh S, Ayesh B, Laster M, Bibi O, Giladi H,
Molnar-Kimber K, Sughayer MA, deGroot N, Hochberg A.. Use of
Transcriptional Regulatory Sequences of Telomerase for Selective Killing of
Cancer Cells. Molecular Therapy 2(5):1-6 (2000)
10) Ohana P, Kopf E., Bibi O., Ayesh S., Ariel I., Schulze E., Schneider T.,
Tykocinski, M., Erdmann V., Laster M., Holthuizen E., deGroot N.,
Hochberg A.. The In Vivo and In Vitro Expression of H19 and IGF-2 Genes
in Human Bladder Carcinoma Cell Lines FEBS Lett. 454(1-2):81-4 (1999)
11) Liebergall M., Jaber S., Laster, M., Segal, D., et al. Ender Nailing of Acute
Humeral Shaft Fractures In Multiple Trauma. Injury. (9-10):577-80 (1997)
12) Hadar, M., Galun, E., Laster, M., Reisner, Y., et al. Human /Mouse Radiation
Chimera Are Capable of Mounting A Human Primary Humoral Response.
Blood. 86(1):398-406, (1995)
13) Galun, E., Eid, A., Rivkind, A., Laster, M., Shouval, D. et al. Hepatitis B
Virus Infection Associated With Hematopoietic Tumors. American Journal
of Pathology. 145(5):1001-7, (1994)
14) Seymour, N., Turk, J., Laster, M. et al. In Vitro Hepatic Insulin Resistance in
Chronic Pancreatitis In The Rat. Journal of Surgical Research. 46:450-
45(1989).